Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Telitacicept in Generalized Myasthenia Gravis
jRCT2031250493Phase 3Recruiting
- Sponsor
- Vor Bio
- Start
- Dec 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in myasthenia gravis (MG) comparing Telitacicept with Placebo (2 arms). Primary endpoint: Change from baseline in MG-ADL score at Week 24. Started Dec 2025; status: recruiting.
02
Drugs
telitacicept
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on jRCT2031250493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250493.